Why has the Polynovo (ASX:PNV) share price tanked 15% in 3 weeks?

Much of the bearish sentiment towards the Polynovo share price can be traced back to its full-year report.

| More on:
A woman sees bad news on her computer screen.

Image source: Getty Images

The Polynovo Ltd (ASX: PNV) share price has not had a good time of it recently.

In the past 3 weeks, shares in the medical device company have tumbled more than 15%.  

Let’s take a look at why investors have been dumping Polynovo shares.

What’s weighing down the Polynovo share price?

The Polynovo share price has had a shocking year thus far.

The pain has continued for shareholders in the last 3 weeks as shares in the biotech continue their slide.

Despite the bearish price action, Polynovo has been scarce with price-sensitive news.

Most recently, the company made headlines after announcing the commencement of its Biomedical Advanced Research and Development Authority (BARDA) funded burn study in the United States.

Shares in Polynovo were given a brief reprieve as the company pursued FDA approval for its NovoSorb BTM product.

In addition, the resignation of the company’s chief operating officer, Dr Anthony Kaye, has also weighed on its shares.

However, much of the bearish sentiment towards the Polynovo share price can be traced back to its full-year report.

How did Polynovo perform in FY21?

Shares in Polynovo tanked late last month, despite releasing fairly robust results for FY21.

The biotech’s report was highlighted by a 32% increase in total revenue of $29.3 million.

Other highlights from Poynovo’s full-year report included:

  • Distributor sales grew by 53% over the year
  • Gross margin increased by 3% from “manufacturing efficiency gains”
  • Corporate and overhead expenses increased by 10% as the business expanded
  • Net profit after tax of $260,000 when adding back in non-cash items
  • Achieved breakeven in FY21

Polynovo flagged strong results in FY22 in all of its markets, including the United States, Europe, United Kingdom, Middle East, Asia, Australia, and New Zealand.

However, investors did not seem impressed with the report, inflicting more selling pressure on the Polynovo share price.

Snapshot of the Polynovo share price

The Polynovo share price jumped off a cliff to start the year.

Shares in the Aussie biotech fell hard and fast in the early months of 2021 following a dour first-half report.

As a result, Polynovo shares have more than halved since the start of the year.

At the time of writing, shares in the biotech have continued their fall, trading more tan 2% lower for the day.  

Should you invest $1,000 in Polynovo right now?

Before you consider Polynovo, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Polynovo wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers